Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly: "I just think this is a decent level to start a position if you don't have any [buy, buy, buy!]." Stream Connecticut News for free, 24/7, wherever you are. Navitas: "That one's done ...

Eli Lilly: "I just think this is a decent level to start a position if you don't have any [buy, buy, buy!]." Navitas: "That one's done...I say take your money out that you put in and then you can ...

Eli Lilly: "I just think this is a decent level to start a position if you don't have any [buy, buy, buy!]." Stream NBC 5 for free, 24/7, wherever you are. Navitas ...

Eli Lilly: "I just think this is a decent level to start a position if you don't have any [buy, buy, buy!]." Stream San Diego News for free, 24/7, wherever you are with NBC 7. Navitas ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger. Over the past six months, Eli Lilly has ...

Two former Eli Lilly executives and their families will donate $20 million to IU Health Foundation — the largest philanthropic gift in the foundation's history — to establish the Institute for ...